<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Preveceutical Medical Inc — News on 6ix</title>
<link>https://6ix.com/company/preveceutical-medical-inc</link>
<description>Latest news and press releases for Preveceutical Medical Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 01 Apr 2026 20:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/preveceutical-medical-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683683a578dffbe2df1695d3.webp</url>
<title>Preveceutical Medical Inc</title>
<link>https://6ix.com/company/preveceutical-medical-inc</link>
</image>
<item>
<title>PreveCeutical Adopts Semi-Annual Financial Reporting</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-adopts-semi-annual-financial-reporting-4</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-adopts-semi-annual-financial-reporting-4</guid>
<pubDate>Wed, 01 Apr 2026 20:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - April 1, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") announces that it has elected to rely on Coordinated Blanket Order 51-933 and move to semi-annual financial reporting ("SAR"). Coordinated Blanket Order 51-93 allows eligible venture issuers listed on the Canadian Securities Exchange (the "CSE") to voluntarily move from a quarterly to a semi-annual financial reporting framework....</description>
</item>
<item>
<title>PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-medical-inc-appoints-raj-s-pruthi-md-mha-facs-as-director</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-medical-inc-appoints-raj-s-pruthi-md-mha-facs-as-director</guid>
<pubDate>Mon, 30 Mar 2026 07:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its Board of Directors.Dr. Pruthi is an accomplished physician-scientist and executive with more than 20...</description>
</item>
<item>
<title>PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-canadian-patent-office-allowance-of-innovative-pain-therapy-technology</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-canadian-patent-office-allowance-of-innovative-pain-therapy-technology</guid>
<pubDate>Wed, 25 Feb 2026 08:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - February 25, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Canadian Patent Office has allowed Canadian Patent Application No. 3127020, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This allowance represents a significant milestone in the protection of PreveCeutical's proprietary technologies aimed at addressing unmet needs</description>
</item>
<item>
<title>PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-filing-patent-delivery-080000637</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-filing-patent-delivery-080000637</guid>
<pubDate>Mon, 09 Feb 2026 08:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce it has filed an International (PCT) patent application on February 5, 2026, having the application no. PCT/US2026/014110, and entitled "Delivery of CNS-active therapeutic agents".The international patent application covers innovative methods and formulations aimed at addressing longstanding challenges in the</description>
</item>
<item>
<title>PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-grant-patent-innovative-120000996</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-grant-patent-innovative-120000996</guid>
<pubDate>Thu, 04 Dec 2025 12:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Australian Patent Office has granted Australian Patent No. AU2020212659, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This patent represents a significant milestone in the development and protection of PreveCeutical's proprietary technologies aimed at addressing...</description>
</item>
<item>
<title>PreveCeutical Medical and BioGene Therapeutics Announce Closing of Plan of Arrangement</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-medical-biogene-therapeutics-announce-120000255</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-medical-biogene-therapeutics-announce-120000255</guid>
<pubDate>Wed, 26 Nov 2025 12:00:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") and BioGene Therapeutics Inc. ("BioGene"), are pleased to announce that, further to its News Releases of September 4, 2025, September 19, 2025, October 10, 2025, October 20, 2025 and November 20, 2025, the previously announced plan of.</description>
</item>
<item>
<title>PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-provides-clarification-news-release-172600707</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-provides-clarification-news-release-172600707</guid>
<pubDate>Thu, 20 Nov 2025 17:26:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its news release of earlier today, the Company wishes to clarify that shareholders of record of November 24, 2025 will be issued new common shares of PreveCeutical and 0.02 of one share of BioGene Therapeutics Inc.About PreveCeuticalPreveCeutical is a health sciences company that develops innovative...</description>
</item>
<item>
<title>PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-provides-plan-arrangement-biogene-120000315</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-provides-plan-arrangement-biogene-120000315</guid>
<pubDate>Thu, 20 Nov 2025 12:00:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its News Releases of September 4, 2025, September 19, 2025, October 10, 2025 and October 20, 2025, the Company announces that it will be completing its previously announced plan of arrangement (the...</description>
</item>
<item>
<title>PreveCeutical Closes Second Tranche of Non-Brokered Private Placement</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-closes-second-tranche-non-110000539</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-closes-second-tranche-non-110000539</guid>
<pubDate>Thu, 30 Oct 2025 11:00:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases of August 5, 2025, September 5, 2025 and October 10, 2025 it has closed a second tranche (the "Second Tranche") of its previously announced $1,200,000 non-brokered private...</description>
</item>
<item>
<title>PreveCeutical Announces Results from Annual General and Special Meeting and Increase to Size of Non-Brokered Private Placement</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-results-annual-general-200000675</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-results-annual-general-200000675</guid>
<pubDate>Fri, 10 Oct 2025 20:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that all resolutions presented at the Company's annual general and special meeting (the "Meeting") held on Friday, October 10, 2025, including the following:the election of Stephen Van Deventer, Makarand Jawadekar, Kathleen Rokita and C. Evan Ballantyne as directors of the Company; the ratification of the...</description>
</item>
<item>
<title>PreveCeutical Announces Mailing and Filing of Annual General and Special Meeting Materials in Connection with a Proposed Arrangement with BioGene Therapeutics</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-mailing-filing-annual-220000364</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-mailing-filing-annual-220000364</guid>
<pubDate>Fri, 19 Sep 2025 22:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that further to its News Release of September 4, 2025, it has filed with the applicable Canadian securities regulatory authorities the management information circular dated September 9, 2025 and related meeting materials of the Company (the "Meeting Materials") for use at the annual general and special meeting (the...</description>
</item>
<item>
<title>PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-closes-initial-tranche-non-205800911</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-closes-initial-tranche-non-205800911</guid>
<pubDate>Fri, 05 Sep 2025 20:58:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news release dated August 5, 2025, it has closed an initial tranche (the "Initial Tranche") of its previously announced $1,000,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 16,162,500 units (each, a "Unit") of the Company at a...</description>
</item>
<item>
<title>PreveCeutical Announces Arrangement Agreement with BioGene Therapeutics</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-arrangement-agreement-biogene-200000216</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-arrangement-agreement-biogene-200000216</guid>
<pubDate>Thu, 04 Sep 2025 20:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (the "Company" or "PreveCeutical") announces that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") dated September 3, 2025 with its subsidiary, BioGene Therapeutics Inc. ("BioGene"), pursuant to which PreveCeutical intends to spin-out 12,000,000 common shares of BioGene (the "BioGene Spinout Shares") to the shareholders of...</description>
</item>
<item>
<title>PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting and Director Resignation</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-rescheduled-date-annual-220000083</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-rescheduled-date-annual-220000083</guid>
<pubDate>Thu, 28 Aug 2025 22:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - August 28, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (the "Company" or "PreveCeutical") announces that, further to its News Release of June 25, 2025, July 8, 2025 and August 5, 2025, it has rescheduled its annual general and special meeting (the "Meeting") from September 29, 2025 to October 10, 2025 due to the necessity to comply with the various requirements in connection with the proposed plan of arrangement. At the..</description>
</item>
<item>
<title>BioGene Therapeutics Inc. Appoints Dr. Francis Tavares, PhD., as Chief Technology Officer</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/biogene-therapeutics-inc-appoints-dr-francis-tavares-phd-as-chief-technology-officer</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/biogene-therapeutics-inc-appoints-dr-francis-tavares-phd-as-chief-technology-officer</guid>
<pubDate>Wed, 20 Aug 2025 11:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed of Dr. Francis Tavares as Chief Technology Officer effective on 19 August, 2025.Dr. Francis</description>
</item>
<item>
<title>BioGene Therapeutics Inc. Appoints Dr. Kamal Albarazanji as Senior Director of Metabolic Research</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/biogene-therapeutics-inc-appoints-dr-kamal-albarazanji-as-senior-director-of-metabolic-research</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/biogene-therapeutics-inc-appoints-dr-kamal-albarazanji-as-senior-director-of-metabolic-research</guid>
<pubDate>Tue, 19 Aug 2025 11:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - August 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Kamal Albarazanji as Senior Director of Metabolic Research effective on 18 August, 2025.</description>
</item>
<item>
<title>PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-rescheduled-date-annual-110000192</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-rescheduled-date-annual-110000192</guid>
<pubDate>Wed, 09 Jul 2025 11:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - July 9, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its News Release of June 25, 2025, it has rescheduled its annual general and special meeting from August 15, 2025 to September 5, 2025 at which the shareholders (the "PreveCeutical Shareholders") of the Company will be asked to approve: the election of Stephen Van Deventer, Makarand Jawadekar, Linnéa Olofsso</description>
</item>
<item>
<title>PreveCeutical Welcomes Dr. Francis Tavares, PhD. As Chief Technology Officer</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-welcomes-dr-francis-tavares-155300193</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-welcomes-dr-francis-tavares-155300193</guid>
<pubDate>Mon, 30 Jun 2025 15:53:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - June 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to have appointed Dr. Francis Tavares as a corporate advisor effective 27 June, 2025.Stephen Van Deventer, CEO of PreveCeutical, commented:"We are thrilled to welcome Dr. Francis</description>
</item>
<item>
<title>PreveCeutical Announces Date for Annual General and Special Meeting</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-date-annual-general-110000906</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-date-annual-general-110000906</guid>
<pubDate>Wed, 25 Jun 2025 11:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has scheduled its annual general and special meeting for August 15, 2025, at which the shareholders (the "PreveCeutical Shareholders") of the Company will be asked to approve: the election of Stephen Van Deventer, Makarand Jawadekar, Linnéa Olofsson, Kathleen Rokita and C. Evan Ballantyne as directors o</description>
</item>
<item>
<title>PreveCeutical Announces Non-Brokered Private Placement</title>
<link>https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-non-brokered-private-211900295</link>
<guid isPermaLink="true">https://6ix.com/company/preveceutical-medical-inc/news/preveceutical-announces-non-brokered-private-211900295</guid>
<pubDate>Wed, 11 Jun 2025 21:19:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 15,000,000 units in the capital of the Company (the "Units") at a price of $0.05 per Unit for gross proceeds of up to $750,000. Each Unit consists of one (1) common share of the Company (each, a "Share") and one-half (1/2) ...</description>
</item>
</channel>
</rss>